Spyre Therapeutics (SYRE) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$11.2 million.
- Spyre Therapeutics' Income towards Parent Company rose 8379.93% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 3068.05%. This contributed to the annual value of -$208.0 million for FY2024, which is 3859.97% up from last year.
- According to the latest figures from Q3 2025, Spyre Therapeutics' Income towards Parent Company is -$11.2 million, which was up 8379.93% from -$36.7 million recorded in Q2 2025.
- Spyre Therapeutics' 5-year Income towards Parent Company high stood at -$6.8 million for Q2 2021, and its period low was -$217.1 million during Q2 2023.
- Moreover, its 5-year median value for Income towards Parent Company was -$24.4 million (2022), whereas its average is -$41.5 million.
- As far as peak fluctuations go, Spyre Therapeutics' Income towards Parent Company tumbled by 87245.44% in 2023, and later surged by 8379.93% in 2025.
- Over the past 5 years, Spyre Therapeutics' Income towards Parent Company (Quarter) stood at -$20.4 million in 2021, then grew by 7.94% to -$18.8 million in 2022, then tumbled by 235.67% to -$63.2 million in 2023, then increased by 10.9% to -$56.3 million in 2024, then soared by 80.14% to -$11.2 million in 2025.
- Its last three reported values are -$11.2 million in Q3 2025, -$36.7 million for Q2 2025, and -$44.8 million during Q1 2025.